On September 9, 2025, Xiamen Innovax Biotech Co., Ltd. (Innovax), a leading biotech company in vaccine innovation, announced a major public health milestone with the administration of the first dose of its Cecolin® 9 (HPV 9-valent vaccine) at the Shitang Community Health Service Center in Haicang District, Xiamen. This landmark event marks the official launch of China’s first independently developed HPV 9-valent vaccine, offering a new layer of protection for females aged 9 to 45 against cervical cancer.

Nine Keys, One Mission: Cecolin®9 Begins Its Global Journey

At 9:09 AM on September 9, 2025, nine golden keys — symbolizing health and protection, were presented to mark the global launch of Cecolin®9. This significant moment highlighted the collaboration among government, industry, and research sectors, demonstrating an enduring commitment to women’s wellness worldwide.

The ceremony included a symbolic key presentation to the first nine mothers and their daughters to receive Cecolin®9, underscoring Innovax’s promise to protect families through innovation. The historic first dose opened a new chapter in global health.

18 Years of Innovation: Delivering a "Chinese Solution"

Cecolin®9, born from 18 years of collaborative research between Innovax and Xiamen University, breaks new ground with its globally pioneering E. coli virus-like particle (VLP) expression platform. This proprietary technology delivers high immunogenicity, robust neutralizing antibody responses, and consistent quality—echoing Innovax’s commitment to advancing vaccine science. This breakthrough offers a "Chinese solution" for global HPV vaccine development.

In clinical trials involving over 10,000 Chinese women aged 9–45—focusing on the two peak infection stages for high-risk HPV in China—the vaccine demonstrated 100% efficacy in preventing persistent cervical infections caused by covered high-risk HPV types over a 12-month period.

A landmark head-to-head study published in The Lancet Regional Health Western Pacific further confirmed Cecolin 9’s comparability with a marketed HPV 9-valent vaccine in immunogenicity and safety, with 100% seroconversion rates across all targeted HPV types and comparable adverse event profiles.

Notably, for girls aged 9 to 17, a two-dose schedule is available, which makes immunization more convenient. It is currently the only HPV 9-valent vaccine in China approved for a two-dose regimen in girls aged 15 to 17.

Beyond the First Dose: Sustained Commitment to Global Health

Cecolin®9’s launch is more than a milestone for Innovax—it expands global access to an affordable, high-quality HPV vaccine, contributing to the WHO’s goal of eliminating cervical cancer. As an integral part of "Healthy China" initiatives, it showcases how Chinese innovation is contributing to solutions for global health gaps.

Cecolin®9 is just the beginning. Innovax will continue developing Chinese vaccines to safeguard women’s health worldwide, turning the promise of ‘enduring well-being’ into reality for every corner of the globe.